European lipodystrophy registry: background and structure

Archive ouverte

von Schnurbein, Julia | Adams, Claire | Akinci, Baris | Ceccarini, Giovanni | D’apice, Maria, Rosaria | Gambineri, Alessandra | Hennekam, Raoul, C M | Jeru, Isabelle | Lattanzi, Giovanna | Miehle, Konstanze | Nagel, Gabriele | Novelli, Giuseppe | Santini, Ferruccio | Santos Silva, Ermelinda | Savage, David, B | Sbraccia, Paolo | Schaaf, Jannik | Sorkina, Ekaterina | Tanteles, George | Vantyghem, Marie-Christine | Vatier, Camille | Vigouroux, Corinne | Vorona, Elena | Araújo-Vilar, David | Wabitsch, Martin

Edité par CCSD ; BioMed Central -

International audience. Abstract Background Lipodystrophy syndromes comprise a group of extremely rare and heterogeneous diseases characterized by a selective loss of adipose tissue in the absence of nutritional deprivation or catabolic state. Because of the rarity of each lipodystrophy subform, research in this area is difficult and international co-operation mandatory. Therefore, in 2016, the European Consortium of Lipodystrophies (ECLip) decided to create a registry for patients with lipodystrophy. Results The registry was build using the information technology Open Source Registry System for Rare Diseases in the EU (OSSE), an open-source software and toolbox. Lipodystrophy specific data forms were developed based on current knowledge of typical signs and symptoms of lipodystrophy. The platform complies with the new General Data Protection Regulation (EU) 2016/679 by ensuring patient pseudonymization, informational separation of powers, secure data storage and security of communication, user authentication, person specific access to data, and recording of access granted to any data. Inclusion criteria are all patients with any form of lipodystrophy (with the exception of HIV-associated lipodystrophy). So far 246 patients from nine centres (Amsterdam, Bologna, Izmir, Leipzig, Münster, Moscow, Pisa, Santiago de Compostela, Ulm) have been recruited. With the help from the six centres on the brink of recruitment (Cambridge, Lille, Nicosia, Paris, Porto, Rome) this number is expected to double within the next one or 2 years. Conclusions A European registry for all patients with lipodystrophy will provide a platform for improved research in the area of lipodystrophy. All physicians from Europe and neighbouring countries caring for patients with lipodystrophy are invited to participate in the ECLip Registry. Study registration ClinicalTrials.gov (NCT03553420). Registered 14 March 2018, retrospectively registered.

Suggestions

Du même auteur

Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Cambridge

Archive ouverte | Mosbah, Héléna | CCSD

International audience. Lipodystrophy syndromes are rare diseases with defects in the development or maintenance of adipose tissue, frequently leading to severe metabolic complications. They may be genetic or acquir...

Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency

Archive ouverte | Kühnen, Peter | CCSD

International audience. Introduction: Individuals with proopiomelanocortin (POMC) or leptin receptor (LEPR) deficiency are young and experience severe obesity, hyperphagia, and comorbidities, which can impair qualit...

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Archive ouverte | Clément, Karine | CCSD

International audience

Chargement des enrichissements...